RxDoctor Payments Data

Vladimir Mathieu, MD

Family Medicine · Naples, FLNPI 1437212719

Payments from drug & device makers

$37,158in general payments, 2019–2025

Across 1,304 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$4K
  • AstraZeneca$4K
  • Novo Nordisk$4K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Boehringer Ingelheim$2K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$1,7055%
  • Travel & lodging$1,5544%
  • Food & beverage$33,82991%
  • Education$700%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.20$4,082
AstraZeneca122$4,046
Novo Nordisk209$3,986
AbbVie(2 entities)84$2,952
Johnson & Johnson57$2,418
Boehringer Ingelheim91$2,322
Amgen(2 entities)82$2,225
Bayer44$1,750
Sanofi-aventis U.S. LLC70$1,439
Lilly USA, LLC78$1,415
Merck60$1,238
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC47$927
Pfizer45$658
GSK26$631
Abbott17$617
Mannkind Corporation26$565
Astellas Pharma US Inc34$506
Esperion Therapeutics, Inc.20$463
Novartis24$445
Biohaven Pharmaceuticals, Inc.12$359
Dexcom, Inc.4$258
Insulet Corporation7$244
Scilex Pharmaceuticals Inc.13$233
Indivior Inc.8$225
Phathom Pharmaceuticals, Inc.6$219
Exact Sciences8$214
Amarin Pharma, Inc.5$200
Teva Pharmaceuticals USA, Inc.5$197
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$196
Biohaven Pharmaceutical Holding Company Ltd.5$194
Inspire Medical Systems, Inc.1$176
Corcept Therapeutics8$172
Takeda Pharmaceuticals U.S.A., Inc.8$136
Sunovion Pharmaceuticals Inc.6$131
Actelion Pharmaceuticals US, Inc.1$125
Noctrix Health, Inc.1$121
Boston Scientific1$117
Xeris Pharmaceuticals, Inc.5$112
Tandem Diabetes Care, Inc.2$86
Radius Health, Inc.3$72
Shield Therapeutics Inc4$67
Neotract Inc.1$64
Idorsia Pharmaceuticals US Inc3$55
Alnylam Pharmaceuticals Inc.2$53
Sanofi Pasteur Inc.2$40
Kowa Pharmaceuticals America, Inc.2$39
Currax Pharmaceuticals LLC3$39
E.r. Squibb & Sons, L.L.C.2$36
Valeritas, Inc.2$34
Almatica Pharma LLC2$30
Regeneron Healthcare Solutions, Inc.1$29
Medtronic1$27
Sumitomo Pharma America, Inc.1$22
Vivus LLC1$20
Jazz Pharmaceuticals Inc.1$20
Adlon Therapeutics L.p.1$20
Optinose US, Inc.1$19
Paratek Pharmaceuticals, Inc.1$19
Scpharmaceuticals Inc.1$19
Axonics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,158 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$273,114
Medicare patients
379
Services billed
24,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin211$271,433
FarxigaDapagliflozin Propanediol191$245,459
OzempicSemaglutide152$184,949
RybelsusSemaglutide54$120,084
JanuviaSitagliptin Phosphate80$85,179
MounjaroTirzepatide39$45,197
EliquisApixaban29$44,545
TrulicityDulaglutide39$39,957
Soliqua 100-33Insulin Glargine/Lixisenatide35$36,927
KerendiaFinerenone20$33,350
XareltoRivaroxaban31$30,194
JanumetSitagliptin Phos/Metformin Hcl24$29,174
MyrbetriqMirabegron25$26,197
TradjentaLinagliptin25$25,996
Repatha SureclickEvolocumab30$20,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$2,322$317,568255 claims
Novo NordiskOzempic, Rybelsus$3,986$305,033206 claims
AstraZenecaFarxiga$4,046$245,459191 claims
MerckJanuvia, Janumet$1,238$114,353104 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$1,415$88,39590 claims
PfizerEliquis, Lyrica$658$57,61541 claims
GSKBreo Ellipta, Trelegy Ellipta$631$39,29246 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,439$36,92735 claims
BayerKerendia$1,750$33,35020 claims
Johnson & JohnsonXarelto$2,418$30,19431 claims
Astellas Pharma US IncMyrbetriq$506$26,19725 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$136$19,42922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →